文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

老年贫血患者的克隆性造血突变谱与动态变化

Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals.
PubMed 文献 · Blood · 2020-01-01

基于Lifelines前瞻性队列,纳入676例≥60岁贫血患者及1:1匹配对照,检测27个驱动基因≥1% VAF的获得性突变。随访44个月显示克隆可扩增或消退,VAF平均仅增加0.56%,较大克隆与死亡风险增加相关。

要点

  • TP53和SF3B1突变在贫血组富集,而DTA突变无差异。
  • 较大克隆(≥5% VAF)与死亡风险增加相关,小克隆不影响总生存。

核心结论

  • 老年贫血患者中克隆性造血更常见,且特定突变(TP53、SF3B1)富集,较大克隆与死亡风险增加相关。

主要发现

  • DTA突变(DNMT3A、TET2、ASXL1)在两组间无差异,但TP53和SF3B1突变在贫血组富集。
  • 随访44个月期间克隆可扩增或消退,VAF平均仅增加0.56%,与是否贫血无关。
  • 较大克隆(≥5% VAF)与死亡风险增加相关,而较小克隆(<5% VAF)不影响总生存。

临床怎么用

  • 对老年贫血患者可考虑评估克隆性造血,尤其是慢性炎症性贫血或不明显因贫血者。
  • 检出较大克隆(≥5% VAF)提示死亡风险增加,需加强随访。

局限性

  • 研究基于特定人群队列,结论外推需谨慎。
  • 随访时间44个月,长期克隆动态未完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia is a major and currently poorly understood clinical manifestation of hematopoietic aging. Upon aging, hematopoietic clones harboring acquired leukemia-associated mutations expand and become detectable, now referred to as clonal hematopoiesis (CH). To investigate the relationship between CH and anemia of the elderly, we explored the landscape and dynamics of CH in older individuals with anemia. From the prospective, population-based Lifelines cohort (n = 167 729), we selected all individuals at least 60 years old who have anemia according to World Health Organization criteria (n = 676) and 1:1 matched control participants. Peripheral blood of 1298 individuals was analyzed for acquired mutations at a variant allele frequency (VAF) of 1% or higher in 27 driver genes. To track clonal evolution over time, we included all available follow-up samples (n = 943). CH was more frequently detected in individuals with anemia (46.6%) compared with control individuals (39.1%; P = .007). Although no differences were observed regarding commonly detected DTA mutations (DNMT3A, TET2, ASXL1) in individuals with anemia compared with control individuals, other mutations were enriched in the anemia cohort, including TP53 and SF3B1. Unlike individuals with nutrient deficiency (P = .84), individuals with anemia of chronic inflammation and unexplained anemia revealed a higher prevalence of CH (P = .035 and P = .017, respectively) compared with their matched control individuals. Follow-up analyses revealed that clones may expand and decline, generally showing only a subtle increase in VAF (mean, 0.56%) over the course of 44 months, irrespective of the presence of anemia. Specific mutations were associated with different growth rates and propensities to acquire an additional hit. In contrast to smaller clones (<5% VAF), which did not affect overall survival, larger clones were associated with increased risk for death.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. van Zeventer IA, de Graaf AO, Wouters HJCM, et al. Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. Blood. 2020. PMID: 32243522. doi:10.1182/blood.2019004362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。